Skip Navigation LinksHome > November/December 2013 - Volume 7 - Issue 6 > HIV Testing and Sexual Risk Reduction Counseling in Office-B...
Journal of Addiction Medicine:
doi: 10.1097/ADM.0b013e3182a3b603
Original Research

HIV Testing and Sexual Risk Reduction Counseling in Office-Based Buprenorphine/Naloxone Treatment

Edelman, E. Jennifer MD, MHS; Moore, Brent A. PhD; Caffrey, Sarah MA; Sikkema, Kathleen J. PhD; Jones, Emlyn S. MD, MPH; Schottenfeld, Richard S. MD; Fiellin, David A. MD; Fiellin, Lynn E. MD

Collapse Box

Abstract

Objectives:

We assessed the feasibility and preliminary efficacy of human immunodeficiency virus (HIV) testing with sexual risk reduction counseling for opioid-dependent patients initiating office-based buprenorphine/naloxone treatment.

Methods:

We conducted a 14-week randomized, controlled trial with 30 patients (original target of 114) assigned to receive buprenorphine/naloxone induction/stabilization and HIV testing with Brief Sexual Risk Management (BSRM) or Enhanced Sexual Risk Management (ESRM). We evaluated process measures and compared outcomes at baseline and during the 3-month follow-up.

Results:

Similar proportions of patients receiving BSRM and ESRM underwent HIV testing (93% vs 80%; P = 0.28) and completed counseling sessions (80% vs 67%; P = 0.40). Brief Sexual Risk Management sessions were shorter than ESRM sessions (15.4 vs 23.4 minutes), with comparable manual adherence (P = 0.80). Outcomes did not vary by BSRM versus ESRM.

Conclusions:

Although the recruitment of opioid-dependent patients with sexual risk behaviors is challenging, HIV testing with sexual risk reduction counseling in office-based buprenorphine/naloxone treatment practice is feasible. Interventions to decrease sexual risk behaviors among a segment of this population are necessary.

© 2013 American Society of Addiction Medicine

    

Login

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.